Development and manufacture of lentiviral vectors

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberCPMP/BWP/2458/03
Published26/05/2005
Effective from01/11/2005
KeywordsGene therapy medicinal product, lentiviral vector, quality, manufacturing, advanced therapy medicinal products (ATMPs), lentivirus, development
DescriptionThis guideline describes quality aspects that are relevant for lentiviral vectors (LV). It applies to LV intended for ex vivo or in vivo application.


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more